Clinical Trials Directory

Trials / Completed

CompletedNCT01095471

13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study

A follow-on, Multi-centre, Open-label, Clinical, Phase 4 Trial to Investigate the Persistence of Serotype-specific Antibodies at 40 Months of Age in Children Who Have Received Either the 7-valent or the 13-valent Pneumococcal Conjugate Vaccine at 2, 4 and 12 Months of Age and Assessing the Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Booster Dose Given at 40 Months of Age

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
100 (estimated)
Sponsor
University of Oxford · Academic / Other
Sex
All
Age
39 Months – 46 Months
Healthy volunteers
Accepted

Summary

This is a follow-on, multi-centre, open-label, clinical trial. The purpose of this trial is to investigate the concentrations of serotype-specific antibodies to IgG included in PCV13 in children who have received either the PCV7 or PCV13 primary immunisation at 2, 4 and 12 months of age. We intend to recruit all interested participants who completed the Wyeth-sponsored PCV13 infant trial study (6096A1-007) at selected study sites (i.e. those that recruited the majority of the children in the original study). The study will start in March 2010, at which time the eldest participants in the 6096A1-007 study will be approximately 42 months of age. There will be two visits per participant, 1 month apart from each other. At visit one, all participants will have a blood test and receive a dose of PCV13. At visit 2, all participants will have a blood test and will be offered the remaining pre-school booster vaccinations unless they have already received them.

Conditions

Interventions

TypeNameDescription
BIOLOGICALPCV13Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.

Timeline

Start date
2010-04-01
Primary completion
2010-12-01
Completion
2011-03-01
First posted
2010-03-30
Last updated
2011-03-22

Locations

4 sites across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT01095471. Inclusion in this directory is not an endorsement.